Core Viewpoint - The company is planning a major asset restructuring by acquiring 100% equity of Weigao Purui, which will enhance its operational capabilities and diversify its business into pharmaceutical packaging materials, specifically pre-filled drug delivery systems and automatic safety drug delivery systems. Group 1: Transaction Overview - The transaction involves the issuance of shares to acquire 100% equity of Weigao Purui from Weigao Co., Weihai Shengxi, and Weihai Ruiming [33] - The transaction is expected to constitute a major asset restructuring and is classified as a related party transaction due to the control of the parties involved [34][35] - The specific transaction price is yet to be determined, pending the completion of auditing and evaluation work [41] Group 2: Impact on Business Operations - Prior to the transaction, the company primarily engaged in the research, production, and sales of medical products in the blood purification field [38] - Post-transaction, the company will expand its main business to include the research, production, and sales of pharmaceutical packaging materials, thereby diversifying its operations [30][38] - The integration of Weigao Purui's technology and product layout is expected to enhance the company's product line and market reach in the pharmaceutical packaging sector [38] Group 3: Financial Implications - The transaction is anticipated to improve the company's total assets, net assets, operating income, and net profit, thereby enhancing overall financial performance [39] - A detailed quantitative analysis of the financial impact will be conducted after the completion of the auditing and evaluation processes [39] Group 4: Strategic Rationale - The transaction aligns with national policies encouraging mergers and acquisitions to enhance corporate quality and competitiveness [28] - The company aims to leverage its existing technology in biopharmaceutical membranes and Weigao Purui's extensive customer base in the biopharmaceutical sector to capture growth opportunities in upstream biopharmaceutical markets [31][32]
山东威高血液净化制品股份有限公司发行股份购买资产暨关联交易预案（摘要）